Clinical Trial Update: Administration of MELPIDA to Determine the Safety and Efficacy for Patients With Spastic Paraplegia Type 50 [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and potential efficacy of MELPIDA in patients with hereditary spastic paraplegia (Spastic Paraplegia Type 50) is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Spastic Paraplegia

Drugs mentioned

• Melpida (AAV9-hAP4M1opt gene therapy)

Snippet

Sponsor: The Hospital for Sick Children | Conditions: Spastic Paraplegia Type 50 | Phase 1 | Status: ACTIVE_NOT_RECRUITING